Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease Pharmacogenetics

Abstract excerpt

Recent studies demonstrate that the therapeutic response in Alzheimer's disease (AD) is genotype-specific. More than 200 genes are potentially associated with AD pathogenesis and neurodegeneration, and approximately 1,400 genes distributed across the human genome account for 20 to 95% of variability in drug disposition and pharmacodynamics. Cytochrome P450 enzymes encoded by genes of the CYP superfamily, such as...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholinesterase and Neurodegenerative Diseases
• Share to Computational Drug Discovery Methods
• Share to Pharmacogenetics and Drug Metabolism